Advancing Parkinson’s Therapy: Stem Cell-Derived Dopaminergic Neuron Transplants Show Promise in Early Clinical Trials
Phase I/II studies demonstrate safety and potential efficacy of hES and iPS cell-derived dopaminergic neuron progenitors in treating Parkinson’s disease
Two recent studies published in Nature in April 2025 report on early-phase clinical trials evaluating the safety and potential efficacy of stem cell-derived dopaminergic neuron progenitor transplantation in patients with Parkinson's disease (PD).
